Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).

Skowronski DM, Sabaiduc S, Leir S, Rose C, Zou M, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Bastien N, Li Y, Jassem A, Krajden M, De Serres G.

Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560-7917.ES.2019.24.46.1900585.

2.

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations.

Gagné A, Wang E, Bastien N, Orain M, Desmeules P, Pagé S, Trahan S, Couture C, Joubert D, Joubert P.

J Thorac Oncol. 2019 Dec;14(12):2062-2070. doi: 10.1016/j.jtho.2019.08.2503. Epub 2019 Sep 5.

PMID:
31494258
3.

Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic.

Skowronski DM, Leir S, De Serres G, Murti M, Dickinson JA, Winter AL, Olsha R, Croxen MA, Drews SJ, Charest H, Martineau C, Sabaiduc S, Bastien N, Li Y, Petric M, Jassem A, Krajden M, Gubbay JB.

Euro Surveill. 2019 Apr;24(15). doi: 10.2807/1560-7917.ES.2019.24.15.1900104.

4.

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.

Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Chan T, Bastien N, Li Y, Krajden M, De Serres G.

Euro Surveill. 2019 Jan;24(4). doi: 10.2807/1560-7917.ES.2019.24.4.1900055.

5.

Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010-2011 to 2017-2018.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Fonseca K, Charest H, Martineau C, Hickman R, Chan T, Jassem A, Petric M, Rose C, Bastien N, Li Y, Krajden M.

Clin Infect Dis. 2019 May 2;68(10):1754-1757. doi: 10.1093/cid/ciy876.

6.

Expression of Genes Associated with Telomere Homeostasis in TP53 Mutant LoVo Cell Lines as a Model for Genomic Instability.

Samassekou O, Bastien N, Yan J, Mai S, Drouin R.

Methods Mol Biol. 2018;1769:253-262. doi: 10.1007/978-1-4939-7780-2_16.

PMID:
29564829
7.

Study of Telomere Dysfunction in TP53 Mutant LoVo Cell Lines as a Model for Genomic Instability.

Samassekou O, Bastien N, Yan J, Mai S, Drouin R.

Methods Mol Biol. 2018;1769:209-230. doi: 10.1007/978-1-4939-7780-2_14.

PMID:
29564827
8.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M.

Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035. Erratum in: Euro Surveill. 2018 Jul;23(30):.

9.

Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009-2011.

Rolfes MA, Gross FL, Flannery B, Meyers AFA, Luo M, Bastien N, Fowler RA, Katz JM, Levine MZ, Kumar A, Uyeki TM; CSIS and ROSII Study Groups.

J Infect Dis. 2018 Mar 13;217(7):1078-1088. doi: 10.1093/infdis/jiy013.

10.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

11.

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y.

J Infect Dis. 2017 Sep 15;216(6):697-702. doi: 10.1093/infdis/jix393.

12.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M.

Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

13.

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y, Smith DJ.

J Infect Dis. 2017 Apr 1;215(7):1059-1099. doi: 10.1093/infdis/jix074.

14.

Transcriptomic Microenvironment of Lung Adenocarcinoma.

Bossé Y, Sazonova O, Gaudreault N, Bastien N, Conti M, Pagé S, Trahan S, Couture C, Joubert P.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):389-396. doi: 10.1158/1055-9965.EPI-16-0604. Epub 2016 Dec 12.

15.

Faster DNA Repair of Ultraviolet-Induced Cyclobutane Pyrimidine Dimers and Lower Sensitivity to Apoptosis in Human Corneal Epithelial Cells than in Epidermal Keratinocytes.

Mallet JD, Dorr MM, Drigeard Desgarnier MC, Bastien N, Gendron SP, Rochette PJ.

PLoS One. 2016 Sep 9;11(9):e0162212. doi: 10.1371/journal.pone.0162212. eCollection 2016.

16.

Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada.

Chaudhry A, Bastien N, Li Y, Scott A, Pabbaraju K, Stewart D, Wong S, Drews SJ.

Influenza Other Respir Viruses. 2016 Nov;10(6):532-535. doi: 10.1111/irv.12415. Epub 2016 Aug 8.

17.

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Krajden M, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Kwindt TL, Bastien N, Li Y.

Clin Infect Dis. 2016 Jul 1;63(1):21-32. doi: 10.1093/cid/ciw176. Epub 2016 Mar 29.

18.

Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.

Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De Serres G, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Krajden M, Bastien N, Li Y.

Euro Surveill. 2016;21(11):30168. doi: 10.2807/1560-7917.ES.2016.21.11.30168.

19.

Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses.

Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, Drews SJ, Martineau C, De Serres G, Dickinson JA, Winter AL, Bastien N, Li Y.

Euro Surveill. 2016;21(3):30112. doi: 10.2807/1560-7917.ES.2016.21.3.30112.

20.

Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015.

Skowronski DM, Chambers C, Gustafson R, Purych DB, Tang P, Bastien N, Krajden M, Li Y.

Emerg Infect Dis. 2016 Jan;22(1):71-4. doi: 10.3201/eid2201.151330.

21.

In Cellulo DNA Analysis: LMPCR Footprinting.

Drouin R, Bastien N, Millau JF, Vigneault F, Paradis I.

Methods Mol Biol. 2015;1334:41-84. doi: 10.1007/978-1-4939-2877-4_4.

PMID:
26404143
22.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
23.

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2015 Jan 29;20(4). pii: 21022. No abstract available.

24.

Influenza in Canada, 2012-2013 season.

Wong E, Yan LY, Bastien N, Sevenhuysen C, Khalil N, Winchester B, Saboui M, Mersereau T.

Can Commun Dis Rep. 2014 Oct 16;40(17):346-354. eCollection 2014 Oct 16.

25.

Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.

Eshaghi A, Shalhoub S, Rosenfeld P, Li A, Higgins RR, Stogios PJ, Savchenko A, Bastien N, Li Y, Rotstein C, Gubbay JB.

Antimicrob Agents Chemother. 2014 Dec;58(12):7188-97. doi: 10.1128/AAC.03667-14. Epub 2014 Sep 22.

26.

Potential human adaptation mutation of influenza A(H5N1) virus, Canada.

Maurer-Stroh S, Li Y, Bastien N, Gunalan V, Lee RT, Eisenhaber F, Booth TF.

Emerg Infect Dis. 2014 Sep;20(9):1580-2. doi: 10.3201/eid2009.140240. No abstract available.

27.

Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.

Samassekou O, Bastien N, Lichtensztejn D, Yan J, Mai S, Drouin R.

Genes Chromosomes Cancer. 2014 Nov;53(11):934-50. doi: 10.1002/gcc.22205. Epub 2014 Jul 25.

PMID:
25059482
28.

Full-genome analysis of avian influenza A(H5N1) virus from a human, North America, 2013.

Pabbaraju K, Tellier R, Wong S, Li Y, Bastien N, Tang JW, Drews SJ, Jang Y, Davis CT, Fonseca K, Tipples GA.

Emerg Infect Dis. 2014 May;20(5):887-91. doi: 10.3201/eid2005.140164.

29.

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y.

PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.

30.

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.

Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, Fonseca K, Gubbay J, Charest H, Petric M, Krajden M, Mahmud S, Van Caeseele P, Kwindt T, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2014 Feb 6;19(5). pii: 20690. Erratum in: Euro Surveill. 2014;19(6):20698.

31.

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.

Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M.

J Infect Dis. 2014 Jul 1;210(1):126-37. Epub 2014 Jan 19.

PMID:
24446529
32.

Genetic characterization of seasonal influenza A (H3N2) viruses in Ontario during 2010-2011 influenza season: high prevalence of mutations at antigenic sites.

Eshaghi A, Duvvuri VR, Li A, Patel SN, Bastien N, Li Y, Low DE, Gubbay JB.

Influenza Other Respir Viruses. 2014 Mar;8(2):250-7. doi: 10.1111/irv.12219. Epub 2013 Dec 6.

33.

Detection of influenza H7N9 virus: all molecular tests are not equal.

Hatchette TF, Drews SJ, Bastien N, Li Y, German G, Antonishyn N, Charest H, Mazzulli T, Fonseca K, Krajden M, Petric M, Dust K, LeBlanc JJ.

J Clin Microbiol. 2013 Nov;51(11):3835-8. doi: 10.1128/JCM.01808-13. Epub 2013 Aug 21.

34.

Cytosine containing dipyrimidine sites can be hotspots of cyclobutane pyrimidine dimer formation after UVB exposure.

Bastien N, Therrien JP, Drouin R.

Photochem Photobiol Sci. 2013 Aug;12(8):1544-54. doi: 10.1039/c3pp50099c.

PMID:
23877442
35.

The 3895-bp mitochondrial DNA deletion in the human eye: a potential involvement in corneal ageing and macular degeneration.

Gendron SP, Bastien N, Mallet JD, Rochette PJ.

Mutagenesis. 2013 Mar;28(2):197-204. doi: 10.1093/mutage/ges071.

PMID:
23408842
36.

A (H1N1) pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico.

Vazquez-Perez JA, Isa P, Kobasa D, Ormsby CE, Ramírez-Gonzalez JE, Romero-Rodríguez DP, Ranadheera C, Li Y, Bastien N, Embury-Hyatt C, González-Duran E, Barrera-Badillo G, Ablanedo-Terrazas Y, Sevilla-Reyes EE, Escalera-Zamudio M, Cobián-Güemes AG, Lopez I, Ortiz-Alcántara J, Alpuche-Aranda C, Perez-Padilla JR, Reyes-Terán G.

Virol J. 2013 Jan 31;10:41. doi: 10.1186/1743-422X-10-41.

37.

Adenovirus serotype 14 infection, New Brunswick, Canada, 2011.

Girouard G, Garceau R, Thibault L, Oussedik Y, Bastien N, Li Y.

Emerg Infect Dis. 2013 Jan;19(1):119-22. doi: 10.3201/eid1901.120423.

38.

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).

Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y.

J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

PMID:
22872731
39.

A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.

Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, Gubbay J, Fonseca K, Charest H, Crowcroft NS, Fradet MD, Bastien N, Li Y, Krajden M, Sabaiduc S, Petric M.

Clin Infect Dis. 2012 Aug;55(3):332-42. doi: 10.1093/cid/cis431. Epub 2012 Apr 26.

PMID:
22539661
40.

Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.

Higgins RR, Beniprashad M, Chong-King E, Li Y, Bastien N, Low DE, Gubbay JB.

J Clin Microbiol. 2012 Jul;50(7):2500-2. doi: 10.1128/JCM.00682-12. Epub 2012 Apr 25.

41.

Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants.

Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, Winter AL, Hottes TS, Fonseca K, Charest H, Drews SJ, Sabaiduc S, Bastien N, Li Y, Gardy JL, Petric M.

J Infect Dis. 2012 Jun 15;205(12):1858-68. doi: 10.1093/infdis/jis283. Epub 2012 Apr 9.

PMID:
22492921
42.

Province-wide adenovirus type 3 outbreak with severe cases in New Brunswick.

Girouard G, Garceau R, Thibault L, Bourque C, Bastien N, Li Y.

Can J Infect Dis Med Microbiol. 2011 Spring;22(1):e4-6.

43.

Mitochondrial DNA common deletion in the human eye: a relation with corneal aging.

Gendron SP, Mallet JD, Bastien N, Rochette PJ.

Mech Ageing Dev. 2012 Feb-Mar;133(2-3):68-74. doi: 10.1016/j.mad.2012.01.002. Epub 2012 Jan 23.

PMID:
22285291
44.

Enrichment of variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU patients: an exploratory study.

La D, Czarnecki C, El-Gabalawy H, Kumar A, Meyers AF, Bastien N, Simonsen JN, Plummer FA, Luo M.

PLoS One. 2011;6(12):e29200. doi: 10.1371/journal.pone.0029200. Epub 2011 Dec 28.

45.

Virulence differences of closely related pandemic 2009 H1N1 isolates correlate with increased inflammatory responses in ferrets.

Meunier I, Embury-Hyatt C, Stebner S, Gray M, Bastien N, Li Y, Plummer F, Kobinger GP, von Messling V.

Virology. 2012 Jan 5;422(1):125-31. doi: 10.1016/j.virol.2011.10.018. Epub 2011 Nov 8.

46.

Runoff infiltration, a desktop case study.

Bastien NR, Arthur S, Wallis SG, Scholz M.

Water Sci Technol. 2011;63(10):2300-8.

PMID:
21977653
47.

Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs.

Bastien N, Gubbay JB, Richardson D, Sleeman K, Gubareva L, Li Y.

J Clin Microbiol. 2011 Nov;49(11):4020-1. doi: 10.1128/JCM.05069-11. Epub 2011 Sep 7. No abstract available.

48.

Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child.

Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, Li Y, Bastien N, Alexander DC, Low DE, Gubbay JB.

Emerg Infect Dis. 2011 Aug;17(8):1472-4. doi: 10.3201/eid1708.102004.

49.

Oseltamivir-resistant pandemic H1N1 influenza.

Webster D, Li Y, Bastien N, Garceau R, Hatchette TF.

CMAJ. 2011 Apr 19;183(7):E420-2. doi: 10.1503/cmaj.100313. Epub 2011 Feb 14. Review. No abstract available.

50.

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, Gubbay JB, Bastien N, Li Y, Petric M.

BMJ. 2011 Feb 3;342:c7297. doi: 10.1136/bmj.c7297.

Supplemental Content

Loading ...
Support Center